Nuveen Asset Management, LLC Graybug Vision, Inc. Transaction History

Nuveen Asset Management, LLC

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 16, 2021	SELL	$3.53 - $6.1 $56,208 - $97,130	-15,923 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$5.55 - $35.0 $28,871 - $182,070	5,202 Added 48.52%	15,923 $88,000
Q4 2020 Feb 16, 2021	BUY	$13.05 - $33.93 $139,909 - $363,763	10,721 New	10,721 $311,000

Ticker GRAY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 21,517,700
Market Cap $63.5M
Description
Graybug Vision, Inc., a clinical-stage biopharmaceutical company, focuses on the development of medicines for the treatment of diseases of the retina and optic nerve. The company's lead product candidate is GB-102, an intravitreal injection of a microparticle depot formulation of sunitinib that is in Phase I/IIa and IIb clinical trials for the t...

Get notified when there are updates to the investment portfolio of Nuveen Asset Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Nuveen Asset Management, LLC with notifications on news.